Corning Jereh to Announce Clinical Study Data of KN026 Combined with KN046 in HER2-Positive Solid Tumors at AACR Annual Meeting 2022

SUZHOU, March 9, 2022 /PRNewswire/ -- Corning Jereh Biopharmaceuticals announced that KN026 (HER2 dual antibody) and KN046 (PD-L1/CTLA-4 dual antibody) combination therapy phase II clinical study data (Study No.

The 100-year-old annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research conferences in the world

Poster topic: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid tumors

First author: Prof.

Poster launch time: April 8, 2022 at 1:00 pm ET

HER2 gene amplification or overexpression is common in breast and gastric cancers, as well as other solid tumors such as colorectal cancer, non-small cell lung cancer, gallbladder cancer, renal pelvis cancer, and pancreatic cancer

KN026-203 is an open-label, phase II, multi-center clinical study designed to evaluate the efficacy and safety of KN026 combined with KN046 in the treatment of HER2-positive solid tumors, mainly based on the objective response rate (ORR) assessed by the investigator according to RECIST 1.

About KN026

KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights.

KN026 has been approved by China's National Medical Products Administration (NMPA) and the U.

About KN046

KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.

KN046 has carried out nearly 20 clinical trials at different stages covering more than 10 types of tumors, including non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer in Australia, the United States and China.

Source: Corning Jerry